{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:39:56Z","timestamp":1791247196911,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003662","name":"Korea Evaluation Institute of Industrial Technology","doi-asserted-by":"publisher","award":["2025-RISE-11-003-03"],"award-info":[{"award-number":["2025-RISE-11-003-03"]}],"id":[{"id":"10.13039\/501100003662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003662","name":"Korea Evaluation Institute of Industrial Technology","doi-asserted-by":"publisher","award":["RS2025-09452988"],"award-info":[{"award-number":["RS2025-09452988"]}],"id":[{"id":"10.13039\/501100003662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["HN21C0264"],"award-info":[{"award-number":["HN21C0264"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A2C2015026"],"award-info":[{"award-number":["2020R1A2C2015026"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-23323759"],"award-info":[{"award-number":["RS-2025-23323759"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00405287"],"award-info":[{"award-number":["RS-2024-00405287"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-02217286"],"award-info":[{"award-number":["RS-2025-02217286"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00351420"],"award-info":[{"award-number":["RS-2024-00351420"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jconrel.2025.114380","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:44:59Z","timestamp":1762011899000},"page":"114380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog\u2013mutant cancer"],"prefix":"10.1016","volume":"389","author":[{"given":"Seong Jin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Rin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jconrel.2025.114380_bb0005","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114380_bb0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0015","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114380_bb0020","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e41354","article-title":"Immunotherapy in colorectal cancer: statuses and strategies","volume":"11","author":"Li","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.114380_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102480","article-title":"Advances in immunotherapy for MMR proficient colorectal cancer","volume":"111","author":"Lote","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114380_bb0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.jconrel.2025.114380_bb0040","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"37","key":"10.1016\/j.jconrel.2025.114380_bb0045","first-page":"5171","article-title":"KRAS mutation testing in metastatic colorectal cancer","volume":"18","author":"Tan","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114380_bb0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrclinonc.2009.111","article-title":"Implications for KRAS status and EGFR-targeted therapies in metastatic CRC","volume":"6","author":"Normanno","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7404","key":"10.1016\/j.jconrel.2025.114380_bb0055","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jconrel.2025.114380_bb0060","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/ijbs.88779","article-title":"Impact of KRAS mutation on the tumor microenvironment in colorectal cancer","volume":"20","author":"Zhou","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jconrel.2025.114380_bb0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.semcdb.2016.06.009","article-title":"Inflammation as a driver and vulnerability of KRAS mediated oncogenesis","volume":"58","author":"Kitajima","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2025.114380_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0075","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114380_bb0080","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114380_bb0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","article-title":"KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition","volume":"41","author":"Adderley","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"issue":"25","key":"10.1016\/j.jconrel.2025.114380_bb0100","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114380_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1252516","article-title":"Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer","volume":"13","author":"Qunaj","year":"2023","journal-title":"Front. Oncol."},{"issue":"7451","key":"10.1016\/j.jconrel.2025.114380_bb0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jconrel.2025.114380_bb0115","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/2159-8290.CD-17-1215","article-title":"PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells","volume":"8","author":"Kim","year":"2018","journal-title":"Cancer Discov."},{"issue":"7659","key":"10.1016\/j.jconrel.2025.114380_bb0120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114380_bb0125","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.7150\/thno.67889","article-title":"Exploiting macropinocytosis for drug delivery into KRAS mutant cancer","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114380_bb0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ceb.2020.06.005","article-title":"Macropinocytosis: insights from immunology and cancer","volume":"65","author":"Stow","year":"2020","journal-title":"Curr. Opin. Cell Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2025.114380_bb0135","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41565-021-00897-1","article-title":"Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer","volume":"16","author":"Li","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114380_bb0140","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1021\/acsnano.8b08246","article-title":"Targeting the oncogene KRAS mutant pancreatic cancer by synergistic blocking of lysosomal acidification and rapid drug release","volume":"13","author":"Kong","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114380_bb0150","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114380_bb0155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41568-023-00660-9","article-title":"Beyond genetics: driving cancer with the tumour microenvironment behind the wheel","volume":"24","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.jconrel.2025.114380_bb0160","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: emerging immunological strategies","volume":"20","author":"Kubli","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114380_bb0165","doi-asserted-by":"crossref","first-page":"1200941","DOI":"10.3389\/fimmu.2023.1200941","article-title":"Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy","volume":"14","author":"Shafqat","year":"2023","journal-title":"Front. Immunol."},{"issue":"7378","key":"10.1016\/j.jconrel.2025.114380_bb0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114380_bb0175","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0185","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114380_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0195","first-page":"47","article-title":"Immunogenic cell death: a step ahead of autophagy in cancer therapy","volume":"3","author":"Gupta","year":"2021","journal-title":"J. Cancer Immunol. (Wilmington)"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.12534","article-title":"Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases","volume":"277","author":"Man","year":"2017","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114380_bb0205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrmicro2070","article-title":"Pyroptosis: host cell death and inflammation","volume":"7","author":"Bergsbaken","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114380_bb0210","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.tcb.2017.05.005","article-title":"Gasdermins: effectors of pyroptosis","volume":"27","author":"Kovacs","year":"2017","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0215","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114380_bb0220","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12943-024-02183-9","article-title":"Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7799","key":"10.1016\/j.jconrel.2025.114380_bb0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","article-title":"Gasdermin E suppresses tumour growth by activating anti-tumour immunity","volume":"579","author":"Zhang","year":"2020","journal-title":"Nature"},{"issue":"7661","key":"10.1016\/j.jconrel.2025.114380_bb0230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114380_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.03.043","article-title":"Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor","volume":"94","author":"Chung","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114380_bb0240","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2024.06.028","article-title":"Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer","volume":"372","author":"Kim","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114380_bb0245","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jconrel.2024.07.074","article-title":"Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying peptide-drug conjugate","volume":"375","author":"Kim","year":"2024","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:49:32Z","timestamp":1781326172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S0168365925009940"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114380","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog\u2013mutant cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114380"}}